Deep Genomics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Deep Genomics Inc. - overview
Established
2014
Location
Toronto, ON, Canada
Primary Industry
Biotechnology
About
Based in Toronto, Canada, and founded in 2014, Deep Genomics Inc. operates as a biotechnology company that offers an AI-based platform to create and produce clinically evaluating therapies for rare diseases. The company has 50 members and was co-founded by Brendan Frey (CEO) and Hui Yuan Xiong. In July 2021, Deep Genomics Inc.
raised USD 180 million in Series C funding led by new investor SB Investment Advisers, with participation from other new investors Alexandria Venture Investments, CPP Investment Board, Fidelity Investments, and other returning investors. The company provides an AI-based machine learning platform that focuses on transformational RNA therapeutics for genetic diseases. Deep Genomics also provides a platform called AI Workbench, which helps detect and solve problems related to the human genome, genetic variants, and vast amounts of data on RNA biology. AI Workbench focuses on the discovery of novel therapeutic targets for diseases such as Gout, Wilson Disease, Niemann-Pick disease type C (NPC), and Frontotemporal dementia (FTD).
Deep Genomics Inc. plans to expand the AI Workbench, scale its pipeline to 30 programs, double its staff to around 160 heads by the end of 2022, and advance four programs into the clinic by 2023.
Current Investors
Khosla Ventures, True Ventures, Future Ventures
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Medical Software
Website
www.deepgenomics.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series C
Total Amount Raised
Subscriber access only
Deep Genomics Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.